NASDAQ$OM
Outset Medical Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Outset Medical reported its financial results for the fourth quarter and full year ended December 31, 2024.
Outset Medical delivered a solid fourth quarter, exceeding prior guidance for revenue and significantly improving gross margin. The company saw strong recurring revenue growth driven by increased utilization of its Tablo system, positioning it for positive momentum into 2025.
- Net revenue for Q4 2024 was $29.5 million, surpassing prior guidance.
- Gross margin improved significantly to 36.5% (37.7% non-GAAP) in Q4 2024, up from 25.3% in Q4 2023.
- Recurring revenue, including Tablo consumables and services, grew 17% year-over-year in Q4 2024.
- Operating expenses decreased by 28% from the prior-year period, reflecting efforts to streamline operations and accelerate profitability.
Headline financials
Revenue & EPS history
Outset Medical · Revenue · Quarterly
$29.5M
Revenue by segment
Outset Medical · $30.4M total across 2 segments · Q3 2023
- Product Revenue$23.5M—77.5%
- Service and Other Revenue$6.83M—22.5%
Forward guidance
Outset Medical provided 2025 revenue guidance between $115 million and $125 million, and non-GAAP gross margin guidance in the high-30% range. The company also expects to use less than $50 million of cash in 2025.
Tailwinds
- Projected revenue growth for 2025.
- Anticipated improvement in non-GAAP gross margin.
- Expected reduction in cash usage for 2025 compared to 2024.
- Continued focus on supporting customers and driving meaningful growth.
- Strengthened balance sheet positioning for cash flow breakeven.
Headwinds
- Revenue guidance range is broad, indicating potential variability.
- Continued cash usage, though reduced, still indicates a need for further financial optimization.
- Macroeconomic factors could impact the company's performance.
- Regulatory actions from the FDA or other bodies could affect operations.
- Competition in the medical technology market could pose challenges.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-2.7%
Avg return
Earnings day
-4.8%
Avg return
5 days after
+0.5%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+33.5%
Q1 2025
Best reaction
-69.6%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.2% | -17.1% | -2.3% | |
| Q4 2025 | -16.3% | -28.4% | -28.3% | |
| Q3 2025 | -48.6% | -61.2% | -64.5% | |
| Q1 2025 | +33.5% | +46.8% | +78.3% | |
| Q4 2024 | +2.1% | -13.0% | -28.7% | |
| Q3 2024 | +23.7% | +36.0% | +91.4% | |
| Q2 2024 | -69.6% | -75.0% | -86.1% | |
| Q1 2024 | -13.7% | -18.2% | +18.7% | |
| Q4 2023 | +1.8% | +9.3% | -40.6% | |
| Q3 2023 | -13.6% | -13.8% | +33.7% | |
| Q2 2023 | -14.6% | -17.5% | -31.8% | |
| Q1 2023 | +8.3% | +3.4% | +15.4% | |
| Q4 2022 | -6.5% | -10.6% | -30.5% | |
| Q3 2022 | +20.2% | +44.2% | +82.5% | |
| Q2 2022 | +21.8% | +23.5% | +18.4% | |
| Q1 2022 | -13.2% | -38.5% | -39.5% | |
| Q4 2021 | +9.5% | +15.9% | +22.6% | |
| Q3 2021 | -0.1% | -4.6% | -22.9% | |
| Q2 2021 | -2.5% | -9.9% | +21.1% | |
| Q1 2020 | -5.6% | -14.4% | -16.7% | |
| Q1 2021 | -9.1% | -11.9% | -17.6% | |
| Q2 2020 | +6.0% | +0.1% | +12.2% | |
| Q4 2020 | +12.5% | +8.9% | +18.4% | |
| Q3 2020 | +5.5% | +29.6% | +8.4% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro